Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

BACKGROUND: Although pancreatic ductal adenocarcinomas (PDAs) widely express HER2, the expression level is generally low. If HER2 expression in PDA cells could be enhanced by treatment with a given agent, then combination therapy with that agent and trastuzumab emtansine (T-DM1), a chemotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kan, Shin, Koido, Shigeo, Okamoto, Masato, Hayashi, Kazumi, Ito, Masaki, Kamata, Yuko, Komita, Hideo, Nagasaki, Eijiro, Homma, Sadamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609140/
https://www.ncbi.nlm.nih.gov/pubmed/26475267
http://dx.doi.org/10.1186/s12885-015-1772-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609140/
https://www.ncbi.nlm.nih.gov/pubmed/26475267
http://dx.doi.org/10.1186/s12885-015-1772-1

Ejemplares similares